The Dermatologist

GFR inhibitor rashes are common—and manageable. 🧫 Culture rapid worsening 💊 Consider isotretinoin 💅 Treat paronychia early ⚠️ Superinfection up to 38% Dermatologists are key in keeping oncology pts on therapy #Oncoderm #EGFRinhibitors #DermTwitter hubs.ly/Q0453ZWQ0

Air pollution & atopic disease—correlation or causation? 🌫️ Test your knowledge of the epidemiologic data linking environmental exposures to AD and allergic disease. #AtopicDermatitis #Allergy #DermTwitter hubs.ly/Q045czrF0

Hyperpigmentation care is shifting beyond hydroquinone. Not all facial pigment is melasma—diagnostic precision matters. #Melasma #Hyperpigmentation #DermTwitter hubs.ly/Q045czKx0

Washed microbiota transplantation improved SCORAD, EASI, and itch scores in moderate-to-severe #AtopicDermatitis—while reshaping gut & skin microbiota. Early data reinforce the gut–skin axis as a potential therapeutic target. #DermTwitter #Microbiome hubs.ly/Q045cpng0

At #MasterclassesInDerm 2026, Dr Heather Goff showed how fillers, fractional CO₂ laser, low-dose tretinoin in rosacea, hyperdilute botox, and antioxidants can improve inflammatory derm disease outcomes. #DermTwitter #AestheticDerm hubs.ly/Q045cl0v0

FDA approves icotrokinra (Icotyde) for mod–severe plaque psoriasis. ✔️ First oral IL-23 receptor antagonist ✔️ ~70% IGA 0/1, 55% PASI90 at wk16 ✔️ Once-daily dosing A major shift toward oral targeted therapy. hubs.ly/Q047kbQv0 #Psoriasis #Dermatology #IL23

Does bariatric surgery improve psoriasis? A systematic review shows ↓ PASI, ↓ DLQI, and reduced systemic therapy use—especially after gastric bypass. #DermTwitter #Psoriasis hubs.ly/Q045c9Hq0

AD update 2026: OX40, IL-31, IL-22, Treg therapy & JAK head-to-head data are reshaping treatment expectations. From durability to disease modification, precision targeting is redefining care. #AtopicDermatitis #Dermatology #JAKinhibitors #Immunology hmpgloballearningnetwork.com/site/thederm/c…

Eyebrow & eyelash loss in #AlopeciaAreata often impacts patients more than scalp loss. Now measurable in trials—and treatable. JAK inhibitors show 25–45% regrowth rates. Document. Photograph. Track. Treat. #DermTwitter #HairLoss bit.ly/4b0UoPB

HS diagnosis still takes ~10 years. At #MasterclassesInDerm 2026: “Multidisciplinary care is not optional.” #HidradenitisSuppurativa #DermTwitter bit.ly/3N8wvO6

Palpable lesion disappears after local anesthetic? Try a ring block infiltration—circumferential anesthesia that preserves central tactile feedback. Ideal for deep lipomas & mobile subcutaneous nodules. #DermSurgery #SurgicalPearls #Mohs bit.ly/4cnAWyU

Dermatomyositis = IFN-driven multisystem disease. At #Masterclasses2026, experts reviewed JAK/TYK2 targeting, steroid tapering data, and phase 3 brepocitinib results in skin-predominant DM. #Dermatomyositis #JAKInhibitors #AutoimmuneDerm bit.ly/4r4dVok

Can early skin barrier therapy alter pediatric AD outcomes? 👶🧴 Test your knowledge on infant barrier interventions & early treatment strategies in atopic dermatitis. #AtopicDermatitis #PedsDerm #Eczema #DermatologyQuiz #SkinBarrier bit.ly/40Frcsy

CTCL Update 🧬 When should you worry in MF/SS? What’s next? Read more #CTCL #Dermatology #MF #SezarySyndrome hubs.ly/Q04542L_0

FDA approves deucravacitinib (Sotyktu) for active PsA — the first TYK2 inhibitor for psoriatic arthritis. Phase 3 trials showed significant ACR20 & MDA responses at week 16. Once-daily 6 mg oral option. hubs.ly/Q046bRpk0 #PsA #PsoriaticArthritis #TYK2

DERM DX 72-year-old man with diabetes presents with bilateral reddish-brown cystic shin lesions, present >20 yrs. One enlarging after trauma. Pruritus + discharge. No pain. What’s your diagnosis? Find out! #DermDX #Dermatology #SkinQuiz hubs.ly/Q04540t50

“Don’t undertreat psoriasis.” — Blauvelt Oral IL-23 inhibitors are emerging with strong efficacy + convenience 💊 High-impact sites = systemic candidates PASI 100 should be the goal Read more 🔗 #Psoriasis #IL23 #TYK2 #DermTwitter hubs.ly/Q045409w0

In AA, eyebrow & eyelash loss may carry a greater psychosocial + functional burden than scalp loss. 👁️ Identity 🗣️ Expression 🛡️ Ocular protection Are you assessing it properly? Take the quiz 🔗 #AlopeciaAreata #DermTwitter #HairLoss hubs.ly/Q045418k0

Vitiligo in 2026: 🔹 Topical & oral JAK inhibitors 🔹 Combo NB-UVB 🔹 Cell-based repigmentation Mechanism-driven care is reshaping outcomes—and expectations. #Vitiligo #JAKInhibitors #DermTwitter hmpgloballearningnetwork.com/site/thederm/c…

A + JAK inhibitors = patience + strategy. ⏳ 6–12 months for regrowth 👁️ Brows/lashes follow similar curves 📉 Taper slowly 🔁 Switching JAKs can still work Clinical insights from Dr Brett King #AlopeciaAreata #JAKInhibitors #DermTwitter hubs.ly/Q0453BlZ0